$ZEAL (-31,9%) The reason for this was that the weight loss of 10.7 percent after 42 weeks fell short of expectations. With the drug Petrelintide, the company, together with $ROG (-3,01%) into the booming market for weight loss drugs, which is currently dominated by Novo Nordisk and Eli Lilly.
Q: https://www.n-tv.de/wirtschaft/der_boersen_tag/Pharma-Aktie-stuerzt-ab-id30438110.html

